Table of Contents
ISRN Oncology
Volume 2011 (2011), Article ID 303128, 5 pages
http://dx.doi.org/10.5402/2011/303128
Review Article

Controversies in the Management of Papillary Thyroid Cancer Revisited

1Department of Surgery, University of Arizona, 1501 N. Campbell Avenue, P.O. Box 245131, Tucson, AZ 85724, USA
2Department of Surgery, University of California, San Francisco, CA 94143, USA

Received 1 July 2011; Accepted 21 July 2011

Academic Editors: A. Berner, A. E. Bilsland, and A. Celetti

Copyright © 2011 Marlon A. Guerrero and Orlo H. Clark. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. S. Cooper, G. M. Doherty, B. R. Haugen et al., “Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 19, no. 11, pp. 1167–1214, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. K. Y. Bilimoria, D. J. Bentrem, C. Y. Ko et al., “Extent of surgery affects survival for papillary thyroid cancer,” Annals of Surgery, vol. 246, no. 3, pp. 375–381, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. E. Kebebew and O. H. Clark, “Differentiated thyroid cancer: “complete” rational approach,” World Journal of Surgery, vol. 24, no. 8, pp. 942–951, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. E. L. Mazzaferri and R. T. Kloos, “Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 4, pp. 1447–1463, 2001. View at Publisher · View at Google Scholar
  5. J. P. Shah, T. R. Loree, D. Dharker, and E. W. Strong, “Lobectomy versus total thyroidectomy for differentiated carcinoma of the thyroid: a matched-pair analysis,” The American Journal of Surgery, vol. 166, no. 4, pp. 331–335, 1993. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Cady, “Papillary carcinoma of the thyroid gland: treatment based on risky group definition,” Surgical Oncology Clinics of North America, vol. 7, no. 4, pp. 633–644, 1998. View at Google Scholar · View at Scopus
  7. L. J. DeGroot, E. L. Kaplan, M. McCormick, and F. H. Straus, “Natural history, treatment, and course of papillary thyroid carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 71, no. 2, pp. 414–424, 1990. View at Google Scholar · View at Scopus
  8. E. L. Mazzaferri and S. M. Jhiang, “Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer,” The American Journal of Medicine, vol. 97, no. 5, pp. 418–428, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. I. D. Hay, C. S. Grant, W. F. Taylor, and W. M. McConahey, “Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system,” Surgery, vol. 102, no. 6, pp. 1088–1095, 1987. View at Google Scholar · View at Scopus
  10. A. R. Shaha, J. P. Shah, and T. R. Loree, “Low-risk differentiated thyroid cancer: the need for selective treatment,” Annals of Surgical Oncology, vol. 4, no. 4, pp. 328–333, 1997. View at Google Scholar · View at Scopus
  11. H. Wanebo, M. Coburn, D. Teates, and B. Cole, “Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer,” Annals of Surgery, vol. 227, no. 6, pp. 912–921, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. B. M. Barney, Y. J. Hitchcock, P. Sharma, D. C. Shrieve, and J. D. Tward, “Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer,” Head and Neck, vol. 33, no. 5, pp. 645–649, 2011. View at Publisher · View at Google Scholar · View at PubMed
  13. K. C. Loh, F. S. Greenspan, L. Gee, T. R. Miller, and P. P. B. Yeo, “Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 11, pp. 3553–3562, 1997. View at Google Scholar · View at Scopus
  14. A. H. Mendelsohn, D. A. Elashoff, E. Abemayor, and M. A. St John, “Surgery for papillary thyroid carcinoma: is lobectomy enough?” Archives of Otolaryngology—Head and Neck Surgery, vol. 136, no. 11, pp. 1055–1061, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. R. Udelsman, E. Lakatos, and P. Ladenson, “Optimal surgery for papillary thyroid carcinoma,” World Journal of Surgery, vol. 20, no. 1, pp. 88–93, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. W. T. Shen, L. Ogawa, D. Ruan, I. Suh, Q. Y. Duh, and O. H. Clark, “Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit,” Surgery, vol. 148, no. 2, pp. 398–403, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. E. L. Mazzaferri, G. M. Doherty, and D. L. Steward, “The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma,” Thyroid, vol. 19, no. 7, pp. 683–689, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. G. Pellegriti, C. Scollo, G. Lumera, C. Regalbuto, R. Vigneri, and A. Belfiore, “Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 8, pp. 3713–3720, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. S. Bonnet, D. Hartl, S. Leboulleux et al., “Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 4, pp. 1162–1167, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. F. Arturi, D. Russo, D. Giuffrida et al., “Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 5, pp. 1638–1641, 1997. View at Google Scholar · View at Scopus
  21. N. G. Iyer and A. R. Shaha, “Management of thyroid nodules and surgery for differentiated thyroid cancer,” Clinical Oncology, vol. 22, no. 6, pp. 405–412, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. C. J. Hughes, A. R. Shaha, J. P. Shah, and T. R. Loree, “Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis,” Head and Neck, vol. 18, no. 2, pp. 127–132, 1996. View at Google Scholar · View at Scopus
  23. C. I. Lundgren, P. Hall, P. W. Dickman, and J. Zedenius, “Clinically significant prognostic factors for differentiated thyroid carcinoma: a populationed-based, nested case-control study,” Cancer, vol. 106, no. 3, pp. 524–531, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. V. Zaydfudim, I. D. Feurer, M. R. Griffin, and J. E. Phay, “The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma,” Surgery, vol. 144, no. 6, pp. 1070–1078, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. J. L. Roh, J. Y. Park, and C. I. Park, “Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone,” Annals of Surgery, vol. 245, no. 4, pp. 604–610, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. T. Carling, W. D. Long III, and R. Udelsman, “Controversy surrounding the role for routine central lymph node dissection for differentiated thyroid cancer,” Current Opinion in Oncology, vol. 22, no. 1, pp. 30–34, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. M. Sywak, L. Cornford, P. Roach, P. Stalberg, S. Sidhu, and L. Delbridge, “Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer,” Surgery, vol. 140, no. 6, pp. 1000–1007, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. J. F. Henry, L. Gramatica, A. Denizot, A. Kvachenyuk, M. Puccini, and T. Defechereux, “Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma,” Langenbecks Archives of Surgery, vol. 383, no. 2, pp. 167–169, 1998. View at Google Scholar · View at Scopus
  29. M. L. White and G. M. Doherty, “Level VI lymph node dissection for papillary thyroid cancer,” Minerva Chirurgica, vol. 62, no. 5, pp. 383–393, 2007. View at Google Scholar · View at Scopus
  30. H. Takami, Y. Ito, T. Okamoto, and A. Yoshida, “Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons,” World Journal of Surgery, vol. 35, no. 1, pp. 111–121, 2010. View at Google Scholar
  31. H. Tala and R. M. Tuttle, “Contemporary post surgical management of differentiated thyroid carcinoma,” Clinical Oncology, vol. 22, no. 6, pp. 419–429, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. F. Vaisman, A. Shaha, S. Fish, and R. M. Tuttle, “Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer,” Clinical Endocrinology, vol. 75, no. 1, pp. 112–119, 2011. View at Publisher · View at Google Scholar · View at PubMed
  33. D. Shibru, K. W. Chung, and E. Kebebew, “Recent developments in the clinical application of thyroid cancer biomarkers,” Current Opinion in Oncology, vol. 20, no. 1, pp. 13–18, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. A. L. Melck, L. Yip, and S. E. Carty, “The utility of BRAF testing in the management of papillary thyroid cancer,” The Oncologist, vol. 15, no. 12, pp. 1285–1293, 2010. View at Publisher · View at Google Scholar · View at PubMed
  35. M. N. Nikiforova, E. T. Kimura, M. Gandhi et al., “BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 11, pp. 5399–5404, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Yip, M. N. Nikiforova, S. E. Carty et al., “Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation,” Surgery, vol. 146, no. 6, pp. 1215–1223, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. M. N. Nikiforova and Y. E. Nikiforov, “Molecular diagnostics and predictors in thyroid cancer,” Thyroid, vol. 19, no. 12, pp. 1351–1361, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. E. Kebebew, J. Weng, J. Bauer et al., “The prevalence and prognostic value of BRAF mutation in thyroid cancer,” Annals of Surgery, vol. 246, no. 3, pp. 466–470, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. R. Elisei, C. Ugolini, D. Viola et al., “BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 10, pp. 3943–3949, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus